MGMT and cancer: The standard protocol, established by the European Organisation for Research and Treatment of Cancer (EORTC) 26981/22981 trial, combines normofractionated RT (60 Gy in 30 fractions) with concomitant temozolomide (TMZ, 75 mg/m2/day), followed by 6 cycles of adjuvant TMZ (150–200 mg/m2/day, 5/28 days), improving overall survival (OS) from 12.1 to 14.6 months, particularly in patients with MGMT promoter methylation (Table 1) [12].